Table 3.

Randomized, controlled trials of tolcapone and entacapone in the Cochrane meta‐analysis

Trial	Duration	Treatment		Patient baseline characteristics
				Age (y)	Disease duration (y)	Levodopa dose (mg/day)
Entacapone trials* (n= 1560)
Brooks and Sagar 2003	24 wk	Placebo	n= 97	65.3	9.4	697.0
		200 mg	n= 203
Fénelon et al. 2003	52 wk	Placebo	n= 63	64.2	(Not available)	(Not available)
			200 mg	n= 99
Im et al. 2002	8 wk	Placebo	n= 99	(Not available)	(Not available)	(Not available)
		(entacapone dose not given)	n= 98
Myllyla et al. 2001	52 wk	Placebo	n= 108	62.2	6.1	634.0
		200 mg	n= 218
Parkinson Study Group. 1997	24 wk	Placebo	n= 102	63.3	11.1	772.0
		200 mg	n= 103
Poewe et al. 2002	24 wk	Placebo	n= 104 (88 fluct.)	61.0	8.9	571.0
		200 mg	n= 197 (172 fluct.)
Rinne et al. 1998	24 wk	Placebo	n= 86	62.7	10.8	703.0
		200 mg	n= 85
Ruottinen and Rinne 1996 ‡	8 wk	Placebo	n= 22	61.3	14.0	905.0
		200 mg	n= 23
Tolcapone trials (n = 1006)
Adler et al. 1998	6 wk	Placebo	n= 72	62.0	10.5	(Not available)
		100 mg t.i.d.	n= 69
		200 mg t.i.d.	n= 74
Baas et al. 1997	3 mo	Placebo	n= 58	63.0	9.8	668.0
		100 mg t.i.d.	n= 60
		200 mg t.i.d.	n= 59
Dupont et al. 1997 ‡†	6 wk	Placebo	n= 33	66.0	(Not available)	662.0
		200 mg t.i.d.	n= 32
Kurth et al. 1997 †	6 wk	Placebo	n= 42	64.5	9.2	(Not available)
		200 mg t.i.d.	n= 40
Myllyla et al. 1997 †	6 wk	Placebo	n= 42	63.0	11.0	734.0
		200 mg t.i.d.	n= 38
Rajput et al. 1997	24 wk	Placebo	n= 66	64.0	10.9	867.4
		100 mg t.i.d.	n= 69
		200 mg t.i.d.	n= 67

*For all entacapone trials, dosing with either placebo or entacapone occurred with each dose of levodopa, up to 10 times daily.

^†Trial also included groups that received nonapproved doses of tolcapone (50 or 400 mg t.i.d.).

^‡Crossover study; all others shown used parallel‐group designs.